Efficacy and Safety of Transarterial Chemoembolization Plus Lenvatinib with or Without Tislelizumab as the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis
Journal of Hepatocellular Carcinoma · 2024-08 · Volume 11 · 1607-1622
DOI: 10.2147/jhc.s472286 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Hepatocellular Carcinoma, 2024-08. Verfasst von Jiayun Jiang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Hepatobiliary Surgery, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, People's Republic of …. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Purpose
To compare the efficacy and safety of transarterial chemoembolization (TACE) plus lenvatinib and tislelizumab (TACE-Len-T) versus TACE plus lenvatinib (TACE-Len) as the first-line treatment for patients with unresectable hepatocellular carcinoma (uHCC). Patients and Methods: This retrospective study included 136 uHCC patients treated with TACE-Len-T or TACE-Len from January 1, 2021, to June 30, 2023. Clinical outcomes including overall survival (OS), progression-free survival (PFS), tumor response and adverse events (AEs) were compared between the two groups. The risk factors affecting OS and PFS were also analyzed.
Results
The median OS and PFS of the TACE-Len-T group were significantly longer than those of the TACE-Len group (Median OS: not reached vs 13.8 months, P 3, and cTACE were independent risk factors for OS, whereas TACE-Len treatment was the only independent risk factor for PFS. The frequency and severity of AEs in the TACE-Len-T group were comparable to those in the TACE-Len group (any grade: 92.6% vs 91.2%, P=0.753; grade 3 or 4: 33.8% vs 32.3%, P=0.855).
Conclusion
TACE-Len-T treatment significantly improved OS, PFS, ORR, and DCR over TACE-Len treatment, with a manageable safety profile in uHCC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Hepatobiliary Surgery, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, People's Republic of China.
- Medical Research Institute, College of Pharmaceutical Sciences, Southwest University, Chongqing, People's Republic of China.
ORCID-Profile: Jiayun Jiang, Yu Fu
Zitieren
APA
Jiang, J., Zhang, H., Lai, J., Zhang, S., Ou, Y., Fu, Y., & Zhang, L. (2024). Efficacy and Safety of Transarterial Chemoembolization Plus Lenvatinib with or Without Tislelizumab as the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis. Journal of Hepatocellular Carcinoma, Volume 11, 1607-1622. https://doi.org/10.2147/jhc.s472286
Vancouver
Jiang J, Zhang H, Lai J, Zhang S, Ou Y, Fu Y, et al. Efficacy and Safety of Transarterial Chemoembolization Plus Lenvatinib with or Without Tislelizumab as the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis. Journal of Hepatocellular Carcinoma. 2024;Volume 11:1607-1622. doi:10.2147/jhc.s472286
BibTeX
@article{Jiang2024,
author = {Jiang, Jiayun and Zhang, Hui and Lai, Jiejuan and Zhang, Shiyu and Ou, Yanjiao and Fu, Yu and Zhang, Leida},
title = {Efficacy and Safety of Transarterial Chemoembolization Plus Lenvatinib with or Without Tislelizumab as the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis},
journal = {Journal of Hepatocellular Carcinoma},
year = {2024},
volume = {Volume 11},
pages = {1607--1622},
doi = {10.2147/jhc.s472286}
}
EUVIMED